Chikungunya infected children are being reported these days, said Dr. Deepal Perera, a specialist at the Lady Ridgeway ...

Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...

Valneva has announced positive outcomes from its Phase III trial of the single-shot IXCHIQ chikungunya virus vaccine in ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

At least one girl and three boys were killed, and three boys injured, during an attack on the Saudi Hospital in the besieged ...

Maharashtra CM reviews GBS cases, instructs officials for treatment arrangements, and coverage under MJPJAY in government ...

A new case of Guillain-Barre Syndrome has been reported in Pune, raising concerns as health officials monitor the situation ...

As Pune grapples with a rare outbreak of Guillain-Barré Syndrome (GBS) with 111 suspected cases, civic authorities have urged ...

Despite these setbacks, 2022 and 2023 marked a career resurgence for him, leading India to a historic Thomas Cup win and ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ®, ...

Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its ...

Valneva (NASDAQ:VALN) ADRs traded higher in the premarket on Tuesday after the French biotech posted additional data for its FDA-approved chikungunya vaccine, Ixchiq, from a Phase 3 trial for ...